Screener
Aurinia Pharmaceuticals AUPH License, collaboration and royalty revenue — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Net product sales | $79,412 | $66,574 | $152,975 | $126,545 |
| License, collaboration and royalty revenue | 3,808 | 3,434 | 7,950 | 5,928 |
| Total revenue | 83,220 | 70,008 | 160,925 | 132,473 |
| Operating expenses | ||||
| Cost of revenue | 6,555 | 7,115 | 13,060 | 15,689 |
| Selling, general and administrative | 23,508 | 26,018 | 45,537 | 46,357 |
| Research and development | 13,050 | 7,432 | 20,520 | 13,175 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue?
- Aurinia Pharmaceuticals (AUPH) reported license, collaboration and royalty revenue — revenue of $3.81M in Q2 2026.
- How has Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue changed year-over-year?
- Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue increased by 10.9% year-over-year, from $3.43M to $3.81M.
- What is the long-term trend for Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue has grown at a 216.3% compound annual growth rate (CAGR), from $117K to $11.71M.
- What does license, collaboration and royalty revenue — revenue mean?
- This metric represents the total revenue generated from licensing intellectual property, collaborative research agreements, and royalty payments derived from commercialized products. It reflects the company's ability to monetize its proprietary technology and partnerships without direct product sales. Monitoring this stream helps investors assess the success of strategic alliances and the long-term value of the company's patent portfolio.
Ask your AI about Aurinia Pharmaceuticals's license, collaboration and royalty revenue — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude